Absci to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in three upcoming investor conferences in September 2024:

• Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5th at 5:35 p.m. ET
• Citi 2024 Global TMT Conference: Fireside chat on September 6th at 8:20 a.m. ET
• H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on September 10th at 12:00 p.m. ET

Interested parties can access live and archived webcasts of these events on Absci's investor relations website at investors.absci.com.

Argus Session date unavailable

+2.84% session move Open Argus

Details

News Market Reaction – ABSI

The recorded move for ABSI in the trading session of this news was +2.84%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

• Morgan Stanley 22^nd Annual Global Healthcare Conference
  Fireside chat on Thursday, September 5^th at 5:35 p.m. Eastern Time
  

• Citi 2024 Global TMT Conference
  Fireside chat on Friday, September 6^th at 8:20 a.m. Eastern Time
  

• H.C. Wainwright 26^th Annual Global Investment Conference
  Fireside chat on Tuesday, September 10^th at 12:00 p.m. Eastern Time
  

Interested parties may access live and archived webcasts of these events on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Absci (ABSI) participate in during September 2024?

Absci (ABSI) will participate in three investor conferences in September 2024: Morgan Stanley 22nd Annual Global Healthcare Conference, Citi 2024 Global TMT Conference, and H.C. Wainwright 26th Annual Global Investment Conference.

When is Absci's (ABSI) fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference?

Absci's (ABSI) fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference is scheduled for Thursday, September 5th, 2024, at 5:35 p.m. Eastern Time.

How can investors access Absci's (ABSI) conference webcasts?

Investors can access live and archived webcasts of Absci's (ABSI) conference events on the company's investor relations website at investors.absci.com.

What type of company is Absci (ABSI) described as in the press release?

Absci (ABSI) is described as a data-first generative AI drug creation company in the press release.